CN113874354A - 吡啶酮类衍生物、其制备方法及其在医药上的应用 - Google Patents

吡啶酮类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN113874354A
CN113874354A CN202080038158.1A CN202080038158A CN113874354A CN 113874354 A CN113874354 A CN 113874354A CN 202080038158 A CN202080038158 A CN 202080038158A CN 113874354 A CN113874354 A CN 113874354A
Authority
CN
China
Prior art keywords
groups
group
compound
alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080038158.1A
Other languages
English (en)
Other versions
CN113874354B (zh
Inventor
张晓敏
张睿
王珏
贺峰
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN113874354A publication Critical patent/CN113874354A/zh
Application granted granted Critical
Publication of CN113874354B publication Critical patent/CN113874354B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)

Abstract

吡啶酮类衍生物、其制备方法及其在医药上的应用。特别地，涉及通式(I)所示的吡啶酮类衍生物、其制备方法及含有该衍生物的药物组合物，以及其作为ATX抑制剂的用途，和其在制备用于治疗癌症或纤维变性疾病或病症的药物中的用途。其中通式(I)的各取代基同说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (32)

  1. PCT国内申请，权利要求书已公开。
CN202080038158.1A 2019-06-04 2020-06-03 吡啶酮类衍生物、其制备方法及其在医药上的应用 Active CN113874354B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910480396 2019-06-04
CN2019104803967 2019-06-04
PCT/CN2020/094126 WO2020244539A1 (zh) 2019-06-04 2020-06-03 吡啶酮类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN113874354A true CN113874354A (zh) 2021-12-31
CN113874354B CN113874354B (zh) 2024-02-20

Family

ID=73653064

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080038158.1A Active CN113874354B (zh) 2019-06-04 2020-06-03 吡啶酮类衍生物、其制备方法及其在医药上的应用

Country Status (3)

Country Link
CN (1) CN113874354B (zh)
TW (1) TW202110831A (zh)
WO (1) WO2020244539A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805204A (zh) * 2022-04-01 2022-07-29 云南师范大学 一种制备4-碘异喹啉-1(2h)-酮类化合物的方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112574094B (zh) * 2020-12-14 2022-07-01 成都大学 吲哚酮衍生物及其制药用途
TW202330514A (zh) * 2021-11-25 2023-08-01 大陸商上海濟煜醫藥科技有限公司 三並環衍生物及其製備方法和應用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101815714A (zh) * 2007-10-05 2010-08-25 默克专利有限公司 治疗癌症的噻唑衍生物
CN102695416A (zh) * 2009-10-29 2012-09-26 金纳斯克公司 激酶抑制剂
WO2014139882A1 (en) * 2013-03-14 2014-09-18 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2014202458A1 (en) * 2013-06-19 2014-12-24 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2019029620A1 (zh) * 2017-08-09 2019-02-14 广州市恒诺康医药科技有限公司 Atx抑制剂及其制备方法和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101815714A (zh) * 2007-10-05 2010-08-25 默克专利有限公司 治疗癌症的噻唑衍生物
CN102695416A (zh) * 2009-10-29 2012-09-26 金纳斯克公司 激酶抑制剂
WO2014139882A1 (en) * 2013-03-14 2014-09-18 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2014202458A1 (en) * 2013-06-19 2014-12-24 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2019029620A1 (zh) * 2017-08-09 2019-02-14 广州市恒诺康医药科技有限公司 Atx抑制剂及其制备方法和应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805204A (zh) * 2022-04-01 2022-07-29 云南师范大学 一种制备4-碘异喹啉-1(2h)-酮类化合物的方法

Also Published As

Publication number Publication date
WO2020244539A1 (zh) 2020-12-10
CN113874354B (zh) 2024-02-20
TW202110831A (zh) 2021-03-16

Similar Documents

Publication Publication Date Title
JP7010935B2 (ja) Ｕｓｐ３０の阻害剤としての活性を有するシアノ置換ヘテロ環
CN112955432B (zh) 稠合芳香环类衍生物、其制备方法及其在医药上的应用
CN108623615B (zh) 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用
CN112272670B (zh) 含二并环类衍生物抑制剂、其制备方法和应用
JP5654715B1 (ja) テトラヒドロイミダゾ［１，５−ｄ］［１，４］オキサゼピン誘導体（ＴＥＴＲＡＨＹＤＲＯＩＭＩＤＡＺＯ［１，５−ｄ］［１，４］ＯＸＡＺＥＰＩＮＥＤＥＲＩＶＡＴＩＶＥ）
EP3580224B1 (en) Ask1 inhibiting agents
CN111606908B (zh) Jak抑制剂化合物及其用途
CN114615981A (zh) Kras g12d抑制剂
CN103562210B (zh) 对pI3K 110δ具有选择性的苯并氧氮杂*化合物及使用方法
KR101982912B1 (ko) 융합된 헤테로사이클릭 화합물, 이의 제조 방법, 약학적 조성물, 및 그 용도
WO2022007979A1 (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN113874354A (zh) 吡啶酮类衍生物、其制备方法及其在医药上的应用
CN107011348A (zh) 作为btk活性的抑制剂的杂芳基吡啶酮和氮杂‑吡啶酮化合物
WO2020238791A1 (zh) 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
CN102459272A (zh) 对P110δ具有选择性的为PI3K抑制剂的二环嘧啶化合物和使用方法
CN107787322B (zh) 三环化合物以及它们作为磷酸二酯酶抑制剂的用途
CN113874015B (zh) Ripk2的噻吩并吡啶抑制剂
EP4129996A1 (en) Novel aminopyrimidine egfr inhibitor
WO2013016999A1 (zh) 杂芳基并嘧啶类衍生物、其制备方法和用途
CN111386275A (zh) 高活性sting蛋白激动剂
CN113825757A (zh) 取代的稠合双环类衍生物、其制备方法及其在医药上的应用
WO2020192750A1 (zh) 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
WO2022033562A1 (zh) 用于治疗重症肺炎的jak抑制剂化合物
CN113493453B (zh) 稠合芳香环类衍生物、其制备方法及其在医药上的应用
WO2019085996A1 (zh) 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant